Intelligent Systems Corporation

What Intelligent Systems Corporation does

Intelligent Systems Corporation is a privately held company headquartered in Norcross, Georgia, founded in 1973, that positions itself as a long-term operator in the creation, growth, and operation of early-stage ventures. Its currently most visible activity is the development of AI-powered computer vision software targeting blue light cystoscopy, an imaging-based procedure used in bladder cancer detection. The AI software is being co-developed with Photocure ASA under a partnership announced on October 15, 2025, which is described in the available record as having produced initial promising testing results.

The company's core product — AI Software for Blue Light Cystoscopy — applies computer vision to medical imaging captured during cystoscopy procedures, with a stated differentiator of improved accuracy and precision in identifying cancerous lesions. The product is positioned for healthcare providers and medical institutions performing bladder cancer diagnostics, addressing the pain points of early diagnosis and detection accuracy. A single primary customer segment, Healthcare Providers, is identified in the available segmentation data, and the only commercial relationship documented is the Photocure co-development partnership, structured as a mutual strategic collaboration intended to support regulatory approval across multiple markets. No marketing channels, distribution arrangements, pricing model, or revenue mechanics are publicly disclosed, and pricing is explicitly noted as not publicly disclosed.

Scale is reported at 251-500 employees, with senior leadership comprising J. Leland Strange as Chairman, President & CEO; Bonnie L. Herron as CFO; and Vice Presidents J. William Goodhew and Francis A. Marks. Beyond the Photocure relationship, no fundraising history, M&A activity, certifications, intellectual property portfolio, or geographic operating footprint is documented in the supplied sources, and the company's public website carries no substantive content beyond a tracking pixel, materially limiting external due diligence.

Name

Intelligent Systems Corporation

Website

https://intelsys.com

Company type

Private

Founded year

1973

Headcount range

251–500 employees

Short description

Norcross, Georgia-based Intelligent Systems Corporation, founded in 1973, develops AI-powered computer vision software for blue light cystoscopy to support early bladder cancer detection, serving healthcare providers in a co-development partnership with Photocure ASA.

Ownership category

akta.pro rank

Product category

Medical Imaging Software

NAICS

Custom Computer Programming Services (541511), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

Keywords

• Medical imaging software
• AI diagnostic tools
• Cancer detection systems
• Urology diagnostics
• Healthcare AI software

Headquarters

HQ city

Norcross

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Core offering

Intelligent Systems Corporation develops AI-powered medical diagnostic software that analyzes medical imaging from blue light cystoscopy procedures to support early bladder cancer detection. The core product is an AI image-analysis tool co-developed with Photocure ASA, designed to assist healthcare providers in identifying cancerous lesions with greater accuracy and to support regulatory approval across multiple markets.

Product overview

Intelligent Systems Corporation offers AI-powered medical diagnostic software for bladder cancer detection. The company's core product is an AI software solution for blue light cystoscopy, developed through a partnership with Photocure ASA. The software analyzes medical imaging data to identify cancerous lesions, with the goal of improving early bladder cancer diagnosis and supporting regulatory approval across multiple markets.

Differentiator

Problem solved

Functional benefit

Products and services

• AI Software for Blue Light Cystoscopy

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

One partnership is on record.

• Photocure ASAcoreStrategic or Co-development Partner · 15 October 2025Photocure and Intelligent Scopes Corporation announced a partnership to develop AI software to support blue light cystoscopy for bladder cancer detection, with initial promising testing results. The collaboration aims to improve early bladder cancer diagnosis and support regulatory approval across multiple markets. The project highlights advances in precision diagnostics and AI-driven medical technology.

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Hologic, Inc.
• Karl Storz SE & Co. KG: Karl Storz is the leading manufacturer of blue light cystoscopy systems and the dominant hardware incumbent in the urology endoscopy market Intelligent Systems is targeting. It is comparable as the platform incumbent whose installed base the AI software ultimately runs on or competes against.
• Stryker Corporation: Stryker is a large diversified medical device and surgical visualization company with growing exposure to AI-enabled imaging in the OR. It is comparable as a broad incumbent that could acquire or replicate Intelligent Systems' narrow AI imaging capability.
• RadNet, Inc. RadNet is a large imaging center operator that has invested heavily in AI imaging partnerships and deployments. It is comparable as a downstream channel and customer for AI imaging software in clinical workflows and as a benchmark for how AI imaging can be commercialized at scale across an outpatient network.
• Olympus Corporation (Medical Systems): Olympus is a global leader in flexible endoscopy and a major provider of blue light cystoscopy platforms, actively integrating AI into its imaging stack. It competes for the same hospital budgets and urology procedure volumes Intelligent Systems is pursuing.

Direct peers

• Photocure ASA: Photocure is the named strategic partner and is the developer of Hexvix/Cysview, the blue light agent used in the very cystoscopy procedure the AI software is designed to read. It is a directly comparable bladder cancer diagnostic company with overlapping product economics and regulatory pathway.

Emerging players

• Paige AI, Inc. Paige builds AI software for cancer detection in pathology and is a recipient of FDA breakthrough designations for its imaging AI. It is comparable as an emerging AI imaging diagnostics company in the cancer-detection space with a similar regulatory and clinical adoption pathway.
• Aidoc Medical, Ltd. Aidoc develops a suite of FDA-cleared AI algorithms for radiology and is deployed across a broad hospital installed base. It is comparable as a multi-application AI imaging company that has demonstrated how a single regulated platform can be expanded across use cases, similar to Intelligent Systems' longer-term platform ambitions.
• Ibex Medical Analytics: Ibex is an AI diagnostics company whose cancer-detection algorithms are deployed in clinical pathology workflows. It is comparable as an AI-first diagnostics company pursuing regulated SaMD clearances and recurring clinical software revenue, similar in go-to-market motion to the cystoscopy AI offering.
• Viz.ai, Inc. Viz.ai is a commercial-stage AI medical imaging company with FDA-cleared algorithms integrated into hospital workflows. It is comparable as a reference point for AI medical imaging companies that have moved from clearance to scaled hospital deployments, providing a benchmark for Intelligent Systems' commercial trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intelligent Systems Corporation